Table 2 Characteristics in patients with metastatic castration-resistant prostate cancer.

From: Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project

Characteristics

n = 95

Median age, years (IQR)

73 (68–76)

Median PSA level, ng/ml (IQR)

13.6 (3.62–70.0)

ISUP grade group, n (%)

 ≤ III

13 (14.0%)

 IV

25 (26.9%)

 V

55 (59.1%)

 NA

2

Lymph node metastasis, n (%)

 Absence

55 (57.9%)

 Presence

40 (42.1%)

Bone metastasis, n (%)

 Absence

14 (14.7%)

 1

18 (18.9%)

 2 or 3

13 (13.7%)

 ≥ 4

50 (52.6%)

Lung metastasis, n (%)

 Absence

81 (85.3%)

 Presence

14 (14.7%)

Liver metastasis, n (%)

 Absence

91 (95.8%)

 Presence

4 (4.2%)

Treatment, n (%)

 Abiraterone

37 (38.9%)

 Enzalutamide

38 (40.0%)

 Taxane

11 (11.6%)

 Others

9 (9.5%)

Treatment line for CRPC, n (%)

 1st line

61 (64.2%)

 2nd line

13 (13.7%)

 3rd line

7 (7.4%)

 ≥ 4th line

14 (14.7%)

  1. IQR interquartile range, ISUP International Society of Urological Pathology, NA not available, PSA prostate-specific antigen
Back to article page